Thomas, C.
https://orcid.org/0000-0003-1146-8891
Mayo Clinic
National Center for Advancing Translational Sciences
Citations 1
Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)
Melani, Christopher , Phelan, J. D., Yang, Y. , Davies‐Hill, Theresa, Simard, Jillian , Huang, Dawei , Thomas, C. , Tosto, Frances A., Juanitez, Anna Marie, Jacob, Allison P. , Simmons, H., Steinberg, Seth M. , Staudt, Louis M. , Wilson, Wyndham H. , Lakhotia, Rahul , Pittaluga, Stefania , Muppidi, Jagan , Thomas, C. J., Ceribelli, Michele , Pradhan, A., Rimsza, Lisa M. , Jaffe, Elaine S. , Roschewski, Mark
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 582-584
